Promising Phase 2 Trial Results for Pembrolizumab in Metastatic Brain Cancer

A phase 2 clinical trial of pembrolizumab has shown promising results, with 42% of patients with metastatic brain cancer benefiting from the treatment. The trial found that pembrolizumab, an immunotherapy, was tolerated and demonstrated clinical benefit in patients with brain metastases.